Determinants of Cervical Cancer Screening Among Women Aged 30-49 Years Old in Four African Countries: A Cross-Sectional Secondary Data Analysis

被引:3
作者
Alie, Melsew Setegn [1 ]
Negesse, Yilkal [2 ]
Ayenew, Mengistu [1 ]
机构
[1] Mizan Tepi Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Publ Hlth, Mizan Aman, Ethiopia
[2] Debre Markos Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Debre Markos, Gojjam, Ethiopia
关键词
cervical cancer; cervical cancer screening; cancer; cervical intraepithelial neoplasia; PREVALENCE; LESIONS;
D O I
10.1177/10732748231195681
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Early-stage cervical cancer screening is essential for providing women with a better chance of receiving effective treatment for precancerous and cancer stages. Delay in cervical cancer screening results in late presentation and cancer metastasis. National-level cervical cancer screening in resource-limited countries was scarce and not well studied in Africa based on national data specifically in Kenya, Cameroon, Nambia, and Zimbabwe. Objective: To determine the prevalence and determinants of cervical cancer screening among eligible women in Kenya, Cameroon, Nambia, and Zimbabwe. Methods: This study analyzed demographic and health survey data from Kenya, Cameroon, Nambia, and Zimbabwe. The data were extracted and analyzed by STATA version 15 and further analysis was done. Intraclass correlation coefficient, median odds ratio, and proportional change in variance were calculated to check the appropriateness of multilevel analysis. Variables with P-value <.25 were selected for multivariable multilevel logistic regression analysis. Finally, statistical significance between dependent and independent variables was assessed by odds ratios and 95% confidence intervals. Results: The prevalence of cervical cancer screening in 4 African countries (Nambia, Kenya, Cameroon, and Zimbabwe) was 23.4 [95%CI: 22.8-24.1]. The determinants identified in this study were women of age 41-50 years [AOR = 1.47; 95% CI 1.24, 1.73], rural residence [AOR =.67; 95% CI.55,.81], women who have their own work [AOR = 1.1; 95% CI 1.0, 1.37], smoking status [AOR = 1.89; 95% CI 1.17, 3.0], age at first birth >=35 [AOR = 5.27; 95% CI 1.29-21.52], condom use [AOR = 1.79; 95% CI 1.46,2.19], husbands having worked [AOR = 1.5; 95% CI 1.08,2.11], rich household wealth [AOR = 1.43; 95% CI 1.13,1.8], and having health insurance [AOR = 2.2; 95% CI 1.8,2.7]. Conclusion: The prevalence of cervical cancer screening in Kenya, Cameroon, Nambia, and Zimbabwe was low as compared to World Health Organization (WHO) recommendations. Age, residence, work status, smoking status, women's age at first birth, condom use, husbands having work, wealth status, and health insurance were the identified determinants of cervical cancer screening. Programme and policy interventions could address younger, rural residence women, poor wealth status women, women without work, and those who never use health insurance for the uptake of cervical cancer screening.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Predicting cervical cancer screening behavior among women in southern Iran: a cross-sectional study with PEN-3 model
    Zahra Hosseini
    Niloofar Seyrafi
    Atefeh Homayuni
    Ali Mouseli
    Atefeh Homayuni
    [J]. BMC Women's Health, 23
  • [42] Cervical cancer screening among women with comorbidities: a cross-sectional examination of disparities from the behavioral risk factor surveillance system
    Austin, Jordyn
    Delgado, Paul
    Gatewood, Ashton
    Enmeier, Mackenzie
    Frantz, Brooke
    Greiner, Benjamin
    Hartwell, Micah
    [J]. JOURNAL OF OSTEOPATHIC MEDICINE, 2022, 122 (07): : 359 - 365
  • [43] Factors related to cervical cancer screening among women of childrearing age: a cross-sectional study of a nationally representative sample in Japan
    Kaso, Misato
    Takahashi, Yoshimitsu
    Nakayama, Takeo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (03) : 313 - 322
  • [44] Factors related to cervical cancer screening among women of childrearing age: a cross-sectional study of a nationally representative sample in Japan
    Misato Kaso
    Yoshimitsu Takahashi
    Takeo Nakayama
    [J]. International Journal of Clinical Oncology, 2019, 24 : 313 - 322
  • [45] The feasibility of new HPV/DNA test as a primary cervical cancer screening method among 35- years- old ever-married women in Kalutara district; a cross-sectional study
    K. C. M. Perera
    N. Mapitigama
    HTCS Abeysena
    [J]. BMC Public Health, 21
  • [46] Socio-demographic determinants of cervical cancer screening uptake among women of child-bearing age in Mangochi, Malawi: a facility-based cross-sectional study
    Felistas Mpachika-Mfipa
    Lucy Ida Kululanga
    Abigail Kazembe
    Dumisani Mfipa
    [J]. BMC Cancer, 22
  • [47] Socio-demographic determinants of cervical cancer screening uptake among women of child-bearing age in Mangochi, Malawi: a facility-based cross-sectional study
    Mpachika-Mfipa, Felistas
    Kululanga, Lucy Ida
    Kazembe, Abigail
    Mfipa, Dumisani
    [J]. BMC CANCER, 2022, 22 (01)
  • [48] Prevalence of self-reported abdominal symptoms among 50–74-years-old men and women eligible for colorectal cancer screening –a cross-sectional study
    Mette Bach Larsen
    Heidi Heinsen Bachmann
    Bo Søborg
    Tinne Laurberg
    Katrine J. Emmertsen
    Søren Laurberg
    Berit Andersen
    [J]. BMC Cancer, 21
  • [49] Prevalence of self-reported abdominal symptoms among 50-74-years-old men and women eligible for colorectal cancer screening -a cross-sectional study
    Larsen, Mette Bach
    Bachmann, Heidi Heinsen
    Soborg, Bo
    Laurberg, Tinne
    Emmertsen, Katrine J.
    Laurberg, Soren
    Andersen, Berit
    [J]. BMC CANCER, 2021, 21 (01)
  • [50] Support for lowering cervical cancer screening age to 25 for women living with HIV: retrospective cross-sectional programmatic data from Botswana
    Doreen Ramogola-Masire
    Surbhi Grover
    Anikie Mathoma
    Barati Monare
    Lesego Gabaitiri
    Lisa Bazzett-Matabele
    GJustus Hofmeyr
    Chelsea Morroni
    Rebecca Luckett
    [J]. BMC Women's Health, 22